PT - JOURNAL ARTICLE AU - Wu, Mengyao AU - Lo, Tak-Ho AU - Li, Liping AU - Sun, Jia AU - Deng, Chujun AU - Chan, Ka-Ying AU - Li, Xiang AU - Yeh, Steve Ting-Yuan AU - Lee, Jimmy Tsz Hang AU - Lui, Pauline Po Yee AU - Xu, Aimin AU - Wong, Chi-Ming TI - Amelioration of non-alcoholic fatty liver disease by targeting G protein-coupled receptor 110: A preclinical study AID - 10.1101/2022.12.07.22283206 DP - 2022 Jan 01 TA - medRxiv PG - 2022.12.07.22283206 4099 - http://medrxiv.org/content/early/2022/12/12/2022.12.07.22283206.short 4100 - http://medrxiv.org/content/early/2022/12/12/2022.12.07.22283206.full AB - Background Recent research has shown that the G protein-coupled receptor 110 (GPR110) is an oncogene. The evidence mainly based on high expression of GPR110 in numerous cancer types; and knockdown GPR110 can reduced the cell migration, invasion, and proliferation. GPR110 is, however, mostly expressed in the liver of healthy individuals. The function of GPR110 in liver has not been revealed. Interestingly, expression level of hepatic GPR110 is dramatically decreased in obese subjects. Here, we examined whether GPR110 has a role in liver metabolism.Methods We used recombinant adeno-associated virus-mediated gene delivery system and antisense oligonucleotide to manipulate the hepatic GPR110 expression level in diet-induced obese mice to investigate the role of GPR110 in hepatic steatosis. The clinical relevance was examined using transcriptome profiling and archived biopsy specimens of liver tissues from non-alcoholic fatty liver disease (NAFLD) patients with different degree of fatty liver.Results The expression of GPR110 in the liver was directly correlated to fat content in the livers of both obese mice and NAFLD patients. Stearoyl-coA desaturase 1 (SCD1), a crucial enzyme in hepatic de novo lipogenesis, was identified as a downstream target of GPR110 by RNA-sequencing analysis. Treatment with the liver-specific SCD1 inhibitor MK8245 and specific shRNAs against SCD1 in primary hepatocytes improved the hepatic steatosis of GPR110-overexpressing mice and lipid profile of hepatocytes, respectively.Conclusions These results indicate GPR110 regulates hepatic lipid metabolism through controlling the expression of SCD1. Down-regulation of GPR110 expression can potentially serve as a protective mechanism to stop the over-accumulation of fat in the liver in obese subjects. Overall, our findings not only reveal a new mechanism regulation the progression of NALFD, but also proposed a novel therapeutic approach to combat NAFLD by targeting GPR110.Fundings This work was supported in part by National Natural Science Foundation of China 81870586 (CMW), 82270941 and 81974117 (JS), Area of Excellence AoE/M-707/18 (AX and CMW), and General Research Fund 15101520 (CMW).HighlightsGPR110 regulates hepatic lipid metabolism.High level of hepatic GPR110 aggravates the progression of NAFLD by inducing SCD1 expression.Reduction in hepatic GPR110 is required to alleviate the progression of NAFLD.Targeting hepatic GPR110 improves hepatic steatosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Natural Science Foundation of China (81870586), Area of Excellence (AoE/M-707/18), and General Research Fund (15101520) to C.M.W., and National Natural Science Foundation of China (82270941, 81974117) to S.J.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All animal procedures were approved by the Animal Subjects Ethics Sub-Committee of the Hong Kong Polytechnic University and were conducted in accordance with the guidelines of the Centralized Animals Facilities (19-20/78-HTI-R-OTHERS). The human study is approved by the Human Ethics Committee of Zhujiang Hospital, Southern Medical University, Guangzhou, China (Number: 2019-KY-097-01).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in the manuscript and supporting file as Supplementary Table 3.